Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,763 articles
📰
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.
📰
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Picard Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PMI
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
📰
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
📰
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
📰
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
📰
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
📰
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
Switching from RBC Wealth Management to Fidelity/Schwab etc.
My family has dealt with our local RBC Wealth Management (USA) office for decades (going back through other pre merger companies). I like the office...
📰
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
📰
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
📰
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
📰
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying The Motley Fool
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
1 High-Yield Dividend Stock That's Too Cheap to Ignore
Sometimes "boring" is the way to go.
📰
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.
📰
INO FINAL DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS LAWYERS, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
TRUBRIDGE ALERT: Bragar Eagel & Squire, P.C. is Investigating TruBridge, Inc. on Behalf of TruBridge Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In TruBridge (TBRG)To Contact Him Directly...
Steve Ballmer Once Recalled Charlie Munger Telling Him: 'I Know, You're Not That Smart' — Here's What The Ex-Microsoft CEO Replied
Steve Ballmer once shared how Charlie Munger bluntly questioned his decision to hold Microsoft stock.
Munger's Blunt Question Put Ballmer On The...
📰
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
UBS Maintains DOCMORRIS AG(ZRSEF.US) With Sell Rating, Raises Target Price to $6.34 - 富途牛牛
UBS Maintains DOCMORRIS AG(ZRSEF.US) With Sell Rating, Raises Target Price to $6.34 富途牛牛
📰
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - POM
NEW YORK, March 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor...
📰
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
NEW YORK, March 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of...
📰
Captain Sandy's Charities and Quantum Marine Stabilizers Announce 2026 Spin-A-Thon to Power Yachting's Next Generation of Talent
n Saturday, March 21 at Quantum's Fort Lauderdale headquarters. The event brings shipyards, crew, suppliers, and industry supporters together...
Foguth Wealth Management LLC. Makes New $734,000 Investment in Eli Lilly and Company $LLY
Foguth Wealth Management LLC. bought a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according...
Foguth Wealth Management LLC. Makes New $734,000 Investment in Eli Lilly and Company $LLY
Foguth Wealth Management LLC. bought a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according...